Compare Danaher Corporation (DHR) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs iShares International Treasury Bond ETF — how do they compare? Danaher Corporation trades at $207.45 (market cap $145.83B), while iShares International Treasury Bond ETF trades at $41.25. The key difference: Danaher Corporation pays a 0.77% dividend while iShares International Treasury Bond ETF pays none, and Danaher Corporation is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DHR | IGOV | |
|---|---|---|
Market Cap | $145.83B | — |
Sector | Health | — |
52-Week High | $242.05 | $43.09 |
52-Week Low | $161.91 | $40.35 |
Enterprise Value | $168.04B | — |
Dividend Yield | 0.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $209.26, up 2.2% today, with strong technical momentum as the price sits above key support levels. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 EPS expected at $1.92. Fundamentals show robust profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst sentiment is overwhelmingly positive with 69% buy ratings and a $202.33 consensus price target. Recent news highlights the acquisition of Masimo and new product launches in its biotechnology segment.
The outlook for DHR remains favorable driven by earnings beats and strategic acquisitions, but investors face risks from elevated valuation multiples and potential macroeconomic headwinds. The stock's current technical overbought condition suggests near-term consolidation may occur, yet long-term growth prospects in life sciences support a bullish stance. Key watch points include Q3 2026 earnings results and integration progress of recent acquisitions.
IGOV, an iShares International Treasury Bond ETF trading as a US stock, is priced at $41.19 with no recent change. Technical indicators show a bullish trend from moving averages, while oscillators are neutral. The asset faces pressure from global inflationary trends and rising interest rates, as highlighted in recent financial news.
The outlook for IGOV is cautious due to its high duration exposure amplifying risks from global rate hikes. Investment opportunities are limited by macroeconomic headwinds, with key risks including capital loss potential from prolonged energy issues and geopolitical tensions affecting international bond markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
